On October 21, 2022, the United States (US) Food and Drug Administration (FDA) approved upadacitinib for the treatment of patients with non-radiographic axial spondyloarthritis (nr-axSpA).¹ The approval was based on the positive results of the SELECT-AXIS 2 phase 3 clinical trial which assessed the safety and efficacy of upadacitinib in adults with active nr-axSpA.¹

The American College of Rheumatology (ACR) published 2 updated guidelines for juvenile idiopathic arthritis (JIA) treatment and management.^1,2 The first guideline discusses nonpharmacologic therapies, medication monitoring, immunizations, and imaging, regardless of the JIA phenotype.¹ The second guideline mainly provides updates for pharmacologic management of JIA, precisely focusing on the treatment of temporomandibular joint (TMJ) arthritis, oligoarthritis and systemic JIA, regardless of the macrophage activation syndrome (MAS).²